Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on March 7, 2006, reporting events occurring on March 1, 2006. The filing details a material definitive agreement entered into by a wholly-owned United Kingdom subsidiary of the Registrant.
Key Financial Metrics and Agreement Details
- Credit Facility: A multicurrency revolving credit facility of £20,000,000 (the "UK Credit Agreement").
- Counterparties: Lender is Barclays Bank PLC; Guarantor is AmerisourceBergen Corporation.
- Maturity Date: March 1, 2009.
- Interest Rates: LIBOR (or EURIBOR for Euro loans) plus a margin ranging from 0.32% to 1.20% based on the Registrant's credit rating.
- Facility Fees: Quarterly fees ranging from 0.055% to 0.275% of the total commitment.
- Usage of Funds: General corporate purposes, investments, and acquisitions. Specifically used to fund the acquisition of Brecon Pharmaceuticals Holdings Limited.
Material Changes and Covenants
The agreement introduces specific financial covenants and restrictions not previously detailed in this filing, including:
- Restrictions on additional indebtedness, liens, distributions, dividends, fundamental changes, asset sales, and investments.
- Requirements to maintain specific leverage and fixed charge coverage ratios.
- The Borrower retains the right to repay obligations or reduce commitments at any time.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance, revenue projections, or management commentary regarding future performance. The primary risk disclosed relates to the new debt obligations and the associated covenants restricting the subsidiary's financial flexibility. The filing does not disclose unusual items or contingencies beyond the terms of the credit agreement.
Investor Verification Checklist
- Verify the impact of the £20,000,000 facility on the company's total consolidated debt load.
- Confirm the current credit rating of AmerisourceBergen to determine the applicable interest margin and facility fee.
- Review the terms of the acquisition of Brecon Pharmaceuticals Holdings Limited to assess strategic fit.
- Monitor compliance with the new leverage and fixed charge coverage ratios imposed by the UK Credit Agreement.